Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1701 to 1710 of 1849 total matches.

Cerivastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998  (Issue 1018)
to the pharmacist for 30 days’ treatment based on wholesale price (AWP) provided by the manufacturer or listed ...
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic acid.
Med Lett Drugs Ther. 1998 Jan 16;40(1018):13-4 |  Show IntroductionHide Introduction

Dofetilide for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • May 15, 2000  (Issue 1078)
have participated in an education program. The cost of 30 days’ treatment with dofetilide 500 µg b.i.d. is $216 ...
Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.
Med Lett Drugs Ther. 2000 May 15;42(1078):41-2 |  Show IntroductionHide Introduction

Lopinavir/Ritonavir: A Protease-inhibitor Combination

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
2 Saquinavir (Fortovase − Roche) 1200 mg tid 641.85 1. Cost for 30 days’ treatment, based on AWP ...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2 |  Show IntroductionHide Introduction

Nebulized Budesonide For Asthma in Children

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
-mg ampule 0.5 mg once daily 126.00 1. Cost of 30 days’ treatment according to AWP listings in Drug ...
The FDA has approved a nebulized suspension of the corticosteroid budesonide for maintenance treatment of persistent asthma in children one to eight years old.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):6-7 |  Show IntroductionHide Introduction

Bivalirudin (Angiomax) For Angioplasty

   
The Medical Letter on Drugs and Therapeutics • Apr 30, 2001  (Issue 1103)
. All patients also took aspirin (300 to 325 mg/day). Death, myocardial infarction, need for urgent ...
Bivalirudin is being promoted as an intravenous (IV) anticoagulant that can be used instead of heparin in patients with unstable angina undergoing coronary angioplasty.
Med Lett Drugs Ther. 2001 Apr 30;43(1103):37-8 |  Show IntroductionHide Introduction

Pediarix - a Combined Vaccine for Infants

   
The Medical Letter on Drugs and Therapeutics • May 12, 2003  (Issue 1156)
alone; low-grade fever in the first 4 days also occurredmoreoftenwithPediarix plus Hib vaccine than ...
A new pentavalent vaccine (Pediarix - GlaxoSmithKline), licensed by the FDA for children 6 weeks to 7 years old, includes the antigens from vaccines already marketed against diphtheria, tetanus and pertussis (Infanrix) and hepatitis B (Engerix-B), and a new inactivated polio component.
Med Lett Drugs Ther. 2003 May 12;45(1156):37-8 |  Show IntroductionHide Introduction

Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004  (Issue 1173)
. Cost for 30 days’ treatment with the maintenance dosage, according to data from retail pharmacies ...
Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha1-blockers cause relaxation of smooth muscle tone in the bladder neck, prostatic capsule and prostatic urethra, relieving symptoms of urinary obstruction.
Med Lett Drugs Ther. 2004 Jan 5;46(1173):1-2 |  Show IntroductionHide Introduction

Stalevo for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • May 10, 2004  (Issue 1182)
. Those who are on different doses of levodopa through the day may require different Stalevo prescriptions ...
Levodopa combined with carbidopa (Sinemet, and others) is the most widely used treatment for patients with Parkinson's disease, but after 2 to 5 years most patients develop troublesome complications (Treatment Guidelines from The Medical Letter 2004; 2:41). The newest treatment for Parkinson's disease patients with end-of-dose "wearing-off" is Stalevo (Novartis), a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone (Comtan) with 3 different doses of levodopa/carbidopa. The rationale for Stalevo is that it permits some patients to take only one pill rather than...
Med Lett Drugs Ther. 2004 May 10;46(1182):39-40 |  Show IntroductionHide Introduction

Second-Generation Antipsychotics - Aripiprazole Revisited

   
The Medical Letter on Drugs and Therapeutics • Oct 10, 2005  (Issue 1219)
(Pfizer) 40-80 mg bid 289 1. Cost for 30 days’ treatment with lowest usual dosage for schizophrenia ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy.
Med Lett Drugs Ther. 2005 Oct 10;47(1219):81-2 |  Show IntroductionHide Introduction

Spinal Decompression Machines

   
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008  (Issue 1287)
reported an increase in pain. 1 Another case series evaluated 250 subjects 30 and 180 days after ...
Spinal decompression machines offer a motorized form of mechanical traction. These devices, which are widely advertised to the public as a noninvasive alternative to surgery, are claimed to relieve low back pain by decompressing discs, improving the flow of nutrients into the disc and rehydrating dried-out discs. Devices cleared by the FDA based on substantial similarity to previously approved power traction devices include the Accu- Spina System, DRS System, DRX9000, Lordex Traction Unit, Spinal Health Elite, SpineMED Decompression Table, SpineRx-LDM and VAX-D Therapeutic Table.
Med Lett Drugs Ther. 2008 Jun 2;50(1287):41-2 |  Show IntroductionHide Introduction